ID Source | ID |
---|---|
PubMed CID | 2131972 |
CHEMBL ID | 1350514 |
CHEBI ID | 149804 |
Synonym |
---|
smr000496794 |
MLS001163269 , |
n-{1-({[3-(dimethylamino)propyl]amino}carbonyl)-2-[5-(3-nitrophenyl)-2-furyl]vinyl}-4-methylbenzamide |
BIM-0037010.P001 |
n-[(z)-3-[3-(dimethylamino)propylamino]-1-[5-(3-nitrophenyl)furan-2-yl]-3-oxoprop-1-en-2-yl]-4-methylbenzamide |
CHEBI:149804 |
CHEMBL1350514 |
AKOS001613881 |
HMS2817I10 |
bdbm78957 |
n-[(z)-3-[3-(dimethylamino)propylamino]-1-[5-(3-nitrophenyl)-2-furanyl]-3-oxoprop-1-en-2-yl]-4-methylbenzamide |
n-[(z)-1-[3-(dimethylamino)propylcarbamoyl]-2-[5-(3-nitrophenyl)-2-furyl]vinyl]-4-methyl-benzamide |
n-[(z)-3-[3-(dimethylamino)propylamino]-1-[5-(3-nitrophenyl)furan-2-yl]-3-oxidanylidene-prop-1-en-2-yl]-4-methyl-benzamide |
cid_2131972 |
(2z)-n-[3-(dimethylamino)propyl]-2-[(4-methylphenyl)formamido]-3-[5-(3-nitrophenyl)furan-2-yl]prop-2-enamide |
SR-01000425611-1 |
sr-01000425611 |
cid 2131972 |
Z57239449 |
Role | Description |
---|---|
anticoronaviral agent | Any antiviral agent which inhibits the activity of coronaviruses. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Class | Description |
---|---|
N-acylglycine | An N-acyl-amino acid in which amino acid specified is glycine. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 22.3872 | 0.0447 | 17.8581 | 100.0000 | AID485341 |
Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 19.9526 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
glp-1 receptor, partial | Homo sapiens (human) | Potency | 11.2202 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
TDP1 protein | Homo sapiens (human) | Potency | 20.3375 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
Smad3 | Homo sapiens (human) | Potency | 35.4813 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
67.9K protein | Vaccinia virus | Potency | 12.1912 | 0.0001 | 8.4406 | 100.0000 | AID720579; AID720580 |
IDH1 | Homo sapiens (human) | Potency | 18.3564 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 50.1187 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 79.4328 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 31.6228 | 0.0103 | 23.8567 | 63.0957 | AID2662 |
muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 25.1189 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
ubiquitin-conjugating enzyme E2 N | Homo sapiens (human) | IC50 (µMol) | 20.0000 | 0.8730 | 10.7219 | 78.4000 | AID493155 |
Replicase polyprotein 1a | Severe acute respiratory syndrome-related coronavirus | Ki | 9.1100 | 0.0075 | 3.2392 | 9.1100 | AID1804126 |
Replicase polyprotein 1ab | Human coronavirus 229E | Ki | 9.1100 | 0.0000 | 0.7332 | 9.1100 | AID1804126 |
Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | IC50 (µMol) | 38.5700 | 0.0040 | 2.9266 | 9.9600 | AID596935 |
Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | Ki | 9.1100 | 0.0075 | 3.0083 | 9.1100 | AID1804126; AID596993 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
DNA repair protein RAD52 homolog isoform a | Homo sapiens (human) | AC50 | 24.7000 | 0.1500 | 12.0662 | 35.2100 | AID652116 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
symbiont-mediated perturbation of host ubiquitin-like protein modification | Replicase polyprotein 1a | Severe acute respiratory syndrome-related coronavirus |
symbiont-mediated perturbation of host ubiquitin-like protein modification | Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
RNA-dependent RNA polymerase activity | Replicase polyprotein 1a | Severe acute respiratory syndrome-related coronavirus |
cysteine-type endopeptidase activity | Replicase polyprotein 1a | Severe acute respiratory syndrome-related coronavirus |
K63-linked deubiquitinase activity | Replicase polyprotein 1a | Severe acute respiratory syndrome-related coronavirus |
K48-linked deubiquitinase activity | Replicase polyprotein 1a | Severe acute respiratory syndrome-related coronavirus |
3'-5'-RNA exonuclease activity | Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus |
RNA-dependent RNA polymerase activity | Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus |
cysteine-type endopeptidase activity | Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus |
mRNA 5'-cap (guanine-N7-)-methyltransferase activity | Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus |
mRNA (nucleoside-2'-O-)-methyltransferase activity | Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus |
5'-3' RNA helicase activity | Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus |
K63-linked deubiquitinase activity | Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus |
K48-linked deubiquitinase activity | Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
double membrane vesicle viral factory outer membrane | Replicase polyprotein 1a | Severe acute respiratory syndrome-related coronavirus |
double membrane vesicle viral factory outer membrane | Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID596935 | Inhibition of SARS coronavirus recombinant 3C-like protease expressed in Escherichia coli BL21(DE3) after 30 mins by FRET based assay | 2011 | Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10 | Virtual screening identification of novel severe acute respiratory syndrome 3C-like protease inhibitors and in vitro confirmation. |
AID596934 | Inhibition of SARS coronavirus recombinant 3C-like protease expressed in Escherichia coli BL21(DE3) at 100 uM after 18 mins by FRET based assay | 2011 | Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10 | Virtual screening identification of novel severe acute respiratory syndrome 3C-like protease inhibitors and in vitro confirmation. |
AID596936 | Competitive inhibition of SARS coronavirus recombinant 3C-like protease expressed in Escherichia coli BL21(DE3) by Dixon plot analysis | 2011 | Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10 | Virtual screening identification of novel severe acute respiratory syndrome 3C-like protease inhibitors and in vitro confirmation. |
AID596993 | Inhibition of SARS coronavirus recombinant 3C-like protease expressed in Escherichia coli BL21(DE3) by Lineweaver-Burk plot analysis | 2011 | Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10 | Virtual screening identification of novel severe acute respiratory syndrome 3C-like protease inhibitors and in vitro confirmation. |
AID1804126 | No assay is provided from Article 10.1021/acs.jmedchem.5b01461: \\An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.\\ | 2016 | Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14 | An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (14.29) | 29.6817 |
2010's | 5 (71.43) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.29) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (14.29%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (85.71%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |